These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2753072)

  • 21. Chronopharmacology of high-dose busulfan in children.
    Vassal G; Challine D; Koscielny S; Hartmann O; Deroussent A; Boland I; Valteau-Couanet D; Lemerle J; Lévi F; Gouyette A
    Cancer Res; 1993 Apr; 53(7):1534-7. PubMed ID: 8453619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
    Mannis GN; Andreadis C; Logan AC; Damon LE; Benet LZ; Ai WZ; Gaensler KM; Kaplan LD; Koplowicz YB; Linker CA; Olin RL; Sayre PH; Smith CC; Sudhindra A; Venstrom JM; Wolf JL; Martin TG
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):377-83. PubMed ID: 25776193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.
    Diestelhorst C; Boos J; McCune JS; Russell J; Kangarloo SB; Hempel G
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):991-1000. PubMed ID: 24061863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomal busulphan: bioavailability and effect on bone marrow in mice.
    Hassan Z; Nilsson C; Hassan M
    Bone Marrow Transplant; 1998 Nov; 22(9):913-8. PubMed ID: 9827821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation.
    Regazzi MB; Locatelli F; Buggia I; Bonetti F; Zecca M; Pregnolato M; Quaglini S
    Clin Pharmacol Ther; 1993 Jul; 54(1):45-52. PubMed ID: 8330465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.
    Kusama M; Kubota T; Matsukura Y; Matsuno K; Ogawa S; Kanda Y; Iga T
    Clin Chim Acta; 2006 Jun; 368(1-2):93-8. PubMed ID: 16448639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation.
    Weil E; Zook F; Oxencis C; Canadeo A; Urmanski A; Waggoner M; Eastwood D; Pasquini M; Hamadani M; Hari P
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):952-957. PubMed ID: 28288949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
    Shaw PJ; Nath C; Berry A; Earl JW
    Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
    Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
    Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
    Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
    Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
    Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relation between the duration of the chronic phase of chronic myeloid leukemia and total dose of busulfan in the first year of the treatment].
    Hellmann A; Koberda J; Baran W
    Acta Haematol Pol; 1990; 21(1):60-5. PubMed ID: 2260409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
    Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
    Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
    Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.